The neutralization of IFN‐γ may be an alternative treatment strategy for COVID‐19‐associated ALI/ARDS, since serum levels of IFN‐γ are higher in patients with COVID‐19 infection. The gene discussed is IFNG; the disease is acute respiratory distress syndrome.